subscribeSubscribe
price-trendAsk Us
Syndax, Incyte pen chronic graft-versus-host disease collab

Syndax, Incyte pen chronic graft-versus-host disease collab
Ben Adams FIERCEBIOTECH
28 Sep 2021
Share Share
Kadmon Announces U.S. Availability of REZUROCK for cGVHD

Kadmon Announces U.S. Availability of REZUROCK for cGVHD
PRESS RELEASE
19 Aug 2021
Share Share
Kadmon Announces belumosudil Added to NCCN Clinical Practice Guidelines

Kadmon Announces belumosudil Added to NCCN Clinical Practice Guidelines
PRESS RELEASE
05 Aug 2021
Share Share
Kadmon`s Chronic GVHD Drug Wins First FDA Approval for Company

Kadmon`s Chronic GVHD Drug Wins First FDA Approval for Company
Kate Goodwin BIOSPACE
20 Jul 2021
Share Share
Kadmon shares jump on FDA approval of Rezurock for chronic GvHD

Kadmon shares jump on FDA approval of Rezurock for chronic GvHD
CHEMDIV
19 Jul 2021
Share Share
Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil

Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil
PRESS RELEASE
11 Mar 2021
Share Share
Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil

Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil
BIOSPACE
07 Dec 2020
Share Share
Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil

Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil
KADMON
05 Nov 2020
Share Share
Kadmon Announces sNDA to the U.S. FDA for Belumosudil

Kadmon Announces sNDA to the U.S. FDA for Belumosudil
BUSINESSINSIADER
30 Sep 2020
Share Share
Kadmon files US application for belumosudil in GVHD

Kadmon files US application for belumosudil in GVHD
Vandana Singh SEEKING ALPHA
30 Sep 2020
Share Share